PDS Biotechnology opened lower at $0.98, compared with its previous close of $1.02. In the last trading session, the stock traded between $0.92 and $1.02. It showed a downward intraday trend.
An investment of $100 made 5 years ago in PDS Biotechnology is now worth
$ 9.41
Resulting in a loss of
$ 90.59 (90.59%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.03 (-3.14%)
Day High
$1.02
Day Low
$0.92
Day Open
$0.98
Prev Close
$1.02
Volume
27,38,631
1W Return
-23.71%
1M Return
-34.79%
3M Return
285.94%
6M Return
-24.00%
1Y Return
-6.79%
Market Cap ($ Mn)
104
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-226.85%
ROCE
-122.87%
EPS (TTM)
$-0.17
1 Week
-23.71%
1 Month
-34.79%
3 Months
285.94%
6 Months
-24.00%
9 Months
38.94%
PDS Biotech closes $11.3M PIPE led by Dr. Soon-Shiong
PDS Biotech raised $11.3 million in gross proceeds from initial PIPE closing. Transaction led by Nant Capital; Dr. Patrick Soon-Shiong joins board. Funds will repay debt and advance PDS0301 into late-stage clinical trials. Contingent milestone closing of $11 million tied to FDA protocol submission. NantWorks granted exclusive option to license PDS0101 cancer vaccine platform.
1mo agoPDS Biotechnology plans 36% workforce cut, removes COO
PDS Biotechnology plans to cut its workforce by 36%. Stephan Toutain removed as COO, effective August 21. No financial details on restructuring costs disclosed.
2mo agoPDS Biotechnology CFO Boesgaard resigns; Bedu-Addo takes interim role
PDS Biotechnology Corporation sees a change in its financial leadership with Lars Boesgaard’s resignation as CFO effective September 12, 2026. CEO Frank Bedu-Addo assumes the role of interim Principal Financial Officer, while Controller Janetta Trochimiuk becomes interim Principal Accounting Officer. The company emphasized that the resignation is amicable and unrelated to operational disputes.
2mo agoPDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY
PDS Biotechnology reported a Q2 EPS of $(0.18), missing the consensus estimate of $(0.13) by 38.46%. This reflects a 14.29% increase in losses compared to the $(0.21) per share loss in the prior year quarter, signaling continued operational challenges despite analyst expectations of a narrower deficit.
3mo agoPDS Biotech shares drop 67% as firm halts PDS0101 to focus on PDS0301
PDS Biotechnology Corporation announced a strategic pivot to prioritize PDS0301 for metastatic colorectal cancer, halting internal funding for PDS0101 Phase 3 trials. Shares dropped 67% to $0.26 amid bearish technical signals, including a death cross and oversold RSI levels.
3mo agoPDS Biotechnology establishes up to $50M stock offering program
PDS Biotechnology has established an at-the-market offering program to sell up to $50 million in common stock through Yorkville Securities and B. Riley Securities. The sales agreement was signed on June 15, 2026. The company's stock trades on The Nasdaq Capital Market under the symbol PDSB.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in PDS Biotechnology is now worth
$ 9.41
Resulting in a loss of
$ 90.59 (90.59%)
Note: Past profits do not guarantee future returns.
